Abbott Laboratories (NYSE:ABT) Stock Holdings Increased by RFG Advisory LLC

RFG Advisory LLC raised its position in Abbott Laboratories (NYSE:ABT - Free Report) by 63.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 20,494 shares of the healthcare product maker's stock after buying an additional 7,980 shares during the quarter. RFG Advisory LLC's holdings in Abbott Laboratories were worth $2,719,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Tallon Kerry Patrick acquired a new stake in shares of Abbott Laboratories during the fourth quarter worth about $200,000. Capital & Planning LLC raised its stake in Abbott Laboratories by 1.2% during the 4th quarter. Capital & Planning LLC now owns 8,673 shares of the healthcare product maker's stock valued at $981,000 after acquiring an additional 100 shares during the last quarter. LaFleur & Godfrey LLC lifted its position in Abbott Laboratories by 23.5% during the 4th quarter. LaFleur & Godfrey LLC now owns 82,443 shares of the healthcare product maker's stock worth $9,325,000 after acquiring an additional 15,692 shares during the period. Brighton Jones LLC grew its stake in shares of Abbott Laboratories by 10.1% in the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker's stock valued at $5,850,000 after purchasing an additional 4,755 shares during the last quarter. Finally, Union Bancaire Privee UBP SA acquired a new position in shares of Abbott Laboratories in the fourth quarter valued at approximately $29,120,000. 75.18% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

ABT has been the topic of a number of analyst reports. Bank of America lifted their price objective on shares of Abbott Laboratories from $133.00 to $150.00 and gave the company a "buy" rating in a research report on Monday, March 10th. The Goldman Sachs Group boosted their price target on shares of Abbott Laboratories from $138.00 to $154.00 and gave the stock a "buy" rating in a research note on Tuesday, March 4th. Morgan Stanley increased their price target on shares of Abbott Laboratories from $117.00 to $127.00 and gave the stock an "equal weight" rating in a report on Thursday, April 17th. Royal Bank of Canada boosted their target price on Abbott Laboratories from $140.00 to $145.00 and gave the stock an "outperform" rating in a research report on Thursday, April 17th. Finally, Raymond James lifted their price target on Abbott Laboratories from $132.00 to $142.00 and gave the company an "outperform" rating in a research note on Thursday, April 17th. Four analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $142.59.

Abbott Laboratories Price Performance

Shares of NYSE ABT traded up $0.73 on Thursday, hitting $133.69. The company's stock had a trading volume of 5,576,936 shares, compared to its average volume of 6,153,382. Abbott Laboratories has a 12-month low of $99.71 and a 12-month high of $141.23. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.60 and a quick ratio of 1.14. The stock has a 50 day moving average of $130.69 and a 200-day moving average of $125.54. The company has a market capitalization of $232.60 billion, a price-to-earnings ratio of 17.48, a price-to-earnings-growth ratio of 2.52 and a beta of 0.74.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 earnings per share for the quarter, topping analysts' consensus estimates of $1.07 by $0.02. The company had revenue of $10.36 billion during the quarter, compared to analysts' expectations of $10.38 billion. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. As a group, research analysts predict that Abbott Laboratories will post 5.14 EPS for the current year.

Insider Activity

In other news, Director Sally E. Blount sold 2,600 shares of the business's stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $129.66, for a total transaction of $337,116.00. Following the completion of the sale, the director now directly owns 34,058 shares of the company's stock, valued at $4,415,960.28. The trade was a 7.09% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.46% of the company's stock.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.